Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBBINGHAUS cognitive function study in FOURIER participants
NL-OMON53170Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia and hypercholesterolemia comparing Evolocumab + statin background therapy with Placebo + statin background therapy (2 arms). Primary endpoint: Spatial Working Memory strategy index. Started Feb 2015; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NL-OMON53170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53170.